N-acetylglucosamine: A new osmotic solute in peritoneal dialysis solutions

Peritoneal Dialysis International

Volumn 17, Issue SUPPL. 2, 1997, Pages

  Breborowicz, Andrzej ^a   Wieczorowska Tobis, Katarzyna ^a   Kuzlan, Malgorzata ^a   Kupsz, Justyna ^a   Korybalska, Katarzyna ^a   Polubinska, Alicja ^a   Krzysztof, Pawlaczyk ^a   French, Ian ^a   Tam, Paul ^a   Wu, George ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Mesothelium; N acetylglucosamine

Indexed keywords

GLUCOSE; HYALURONIC ACID; N ACETYLGLUCOSAMINE; OSMOTIC AGENT;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSATE; HUMAN; HUMAN CELL; MESOTHELIUM CELL; MOLECULAR WEIGHT; NONHUMAN; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERMEABILITY; PRIORITY JOURNAL; RAT; SIDE EFFECT;

EID: 9844229059     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089701702s16     Document Type: Conference Paper

References (20)

1. Coles GA. Biocompatibility of various osmotic solutes. Perit Dial Int 1995; 15:S71-5.
2. Vanholder RC. Lameire NH. Osmotic agents in peritoneal dialysis. Kidney Int 1996; 50 (Suppl 56): S86-1.
3. Dawnay A. Advanced glycation end products in peritoneal dialysis. Perit Dial Int 1996; 16 (Suppl 1):S50-3.
4. Wu G, Breborowicz A, Korybalska K, et al. Use of N-Acetyl-Glucosamine as osmotic agent for peritoneal dialysis. Perit Dial Int 1996; 16 (Suppl 2):S16.
5. Yung S, Coles GA, Williams JD, et al. The source and possible significance of hyaluronan in the peritoneal cavity. Kidney Int 1994; 46:527-33.
6. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991; 71:481-532.
7. Comper WD, Laurent TC. Physiological function of connective tissue polysaccharides.Physiol Rev 1978; 58:255-325.
8. Weigel PH, Frost SJ, LeBoeuf R, et al. The specific interaction between fibrin(ogen) and hyaluronan: possible consequences in haemostasia, inflammation and wound healing. In: Evered D, Whelan J, eds. The biology of hyaluronan. Chichester: Wiley (Ciba Foundation Symposium 143) 1989; 248-64.
9. Wieczorowska K, Breborowicz A, Martis L, et al. Protective effect of hyaluronic acid against peritoneal injury. Perit Dial Int 1995; 15:81-3.
10. Wu G, Wieczorowska-Tohis K, Tam P, et al. N-AcetylGlucosamine (NAG) protects peritoneum of rats on chronic peritoneal dialysis. Perit Dial Int 1997; 17:(Suppl 1):S10.
11. Breborowicz A, Radkowski M, Knapowski J, et al. Effects of chondroitin sulphate on fluid and solute transport during peritoneal dialysis in rats. Perit Dial Int 1991; 11:351-4.
12. Hain H, Kessel M. Aspects of new solutions for peritoneal dialysis. Nephrol Dial Transpl 1987; 2:67-72.
13. Levin RM, Krieger NN, Wiznler RJ. Glucosamine and acetylglucosamine tolerance in man. J Lab Clin Med 1961; 58:927-32.
14. Weiden S, Wood IJ. The fate of glucosamine hydrochloride injected intravenously in man. J Clin Pathol 1958; 11:343-9.
15. Kohn P, Winzler RJ, Hoffman RC. Metabolism of D-Glucosamine and N-Acetyl-D-glucosamine in the intact rat. J Biol Chem 1962; 237:304-8.
16. Breborowicz A, Wieczorowska K, Martis L, et al. Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron 1994; 67:346-50.
17. Bazzato G, Fracasso A, Re G, et al. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet 1995; 346:740-1.
18. Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; 2:178-82.
19. Westergren-Thorsson G, Onnervik P.O, Franson LA, et al. Proliferation of cultured fibroblasts is inhibited by 1-iduronate-containing glycosaminoglycans. J Cell Physiol 1991; 147:523-30.
20. Gambaro G, Fracasso A, Re G, et al. Glycosaminoglycans improve peritoneal transport and fibrosis in rats with peritoneal sclerosis induced by diethylexylphtalate. J Am Soc Nephrol 1994; 5:448.